Cargando…
COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie
INTRODUCTION: COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400 mg every 6 weeks, nivolumab to 480 mg every 4 weeks. The objective of our study was to assess the impact on quality of life, and on psychological state, as well as the toler...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SPLF. Published by Elsevier Masson SAS.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241593/ https://www.ncbi.nlm.nih.gov/pubmed/34246519 http://dx.doi.org/10.1016/j.rmr.2021.06.005 |